Heterocyclic Compounds, Bridged-RingIndinavirLamivudineAnti-HIV AgentsHIV InfectionsDrug Resistance, ViralHIV Protease InhibitorsDrug Therapy, CombinationStavudineOrganophosphonatesZidovudineHepatitis B, ChronicReverse Transcriptase InhibitorsAdenineHIV-1Antiviral AgentsTreatment OutcomeRitonavirAnti-Retroviral AgentsViral LoadSaquinavirHepatitis B virusHIVHIV ProteaseDrug TherapyLost to Follow-UpInterferon-alphaNelfinavirHepatitis B e AntigensAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountBenzoxazinesHIV Reverse TranscriptaseTreatment FailureOxazinesDrug Resistance, Multiple, ViralDrug Administration ScheduleDideoxynucleosidesPyrimidinonesNevirapineHepatitis BMutationHIV SeropositivityDrug InteractionsDidanosineNamibiaArea Under CurveRNA, ViralLopinavirTime FactorsWorld Health OrganizationGenotypePatient ComplianceDNA, ViralDrug CombinationsRecurrenceDried Blood Spot TestingMedication AdherenceDouble-Blind MethodAlanine TransaminaseDose-Response Relationship, DrugProspective StudiesRetrospective StudiesHepatitis B Surface AntigensAdministration, OralCohort StudiesCarbamatesGenotyping TechniquesDrug MonitoringAcquired Immunodeficiency SyndromeFollow-Up StudiesAntineoplastic Combined Chemotherapy ProtocolsAntitubercular AgentsPrevalenceSentinel SurveillanceNucleosidesCameroonGuanineAntineoplastic AgentsCytochrome P-450 CYP3AHIV SeroprevalenceCombined Modality TherapyPyuriaDrug Resistance, MicrobialPopulation SurveillanceAntihypertensive AgentsDeveloping CountriesRisk FactorsClinical Trials as TopicDrug CostsHepatitis B AntibodiesCross-Over StudiesGene Products, polDrug ResistanceHIV SeronegativityCost-Benefit AnalysisSophoraRandomized Controlled Trials as TopicSubstance Abuse Treatment CentersAnti-Bacterial Agents